Beating Infections through Research and Development Act of 2007

Bill: 110-hr-1496
Sponsor: Rep. Baird, Brian [D-WA-3]
Introduced: 2007-03-13 in the House
Policy area: Health
Subjects: Administrative procedure
Antibiotics
Biotechnology
Clinical trials
Commerce
Communicable diseases
Congressional reporting requirements
Department of Health and Human Services
Drug approvals
Drug industry
Drug resistance in microorganisms
Executive reorganization
Federal advisory bodies
Food and Drug Administration (FDA)
Government Operations and Politics
Government paperwork
Income tax
Influenza
Intellectual property
Investment tax credit
Law
Medical tests
Patents
Pharmaceutical research
Public health
Research and development
Research and development tax credit
Science, Technology, Communications
Small business
State laws
Surveys
Tax administration
Taxation
Vaccines

Summary:
action_date: 2007-03-13
text: 
 Beating Infections through Research and Development Act of 2007 - Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.

Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.

Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.

Establishes the Commission on Infectious Diseases Product Development to identify drug-resistant infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.


Legislative actions:
action_date: 2007-04-20
text: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
action_date: 2007-03-14
text: Referred to the Subcommittee on Health.
action_date: 2007-03-13
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-03-13
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-03-13
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-03-13
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-03-13
text: Introduced in House
action_date: 2007-03-13
text: Introduced in House